http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2011117392-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0c73717982f3deb188dd22dabeb9b5d5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b3ca021f2871bd6355d556ce7075fdee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6f84939730926b4a161c729e85371b15 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bf2d7fdb486b68871d79488d0dccae76 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a9ba43273fc1c62afed39d91c7dad82c |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2035-124 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-39 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2035-122 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5047 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-15 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0645 |
| classificationIPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-12 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50 |
| filingDate | 2011-03-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f6d8d896cd13c9aa8211813942d9e822 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0d89f14e54220134ca7ef47f12332b8f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ecb6a017063f6ed9abcba9943647288c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3829dced558bf46d5359101788d9390e |
| publicationDate | 2011-09-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2011117392-A2 |
| titleOfInvention | Substitute therapy for glucocorticoids |
| abstract | The present invention relates to a pharmaceutical composition comprising glucocorticoid (GC)-induced human monocytes, and optionally a pharmaceutically acceptable carrier. The present invention further relates to a pharmaceutical composition comprising GC and optionally a pharmaceutically acceptable carrier, for use in the treatment of a disease which is GC-responsive, wherein said pharmaceutical composition is to be administered to human monocytes ex vivo. The pharmaceutical composition may be used for treatment of a disease which is GC-responsive. In another aspect, the present invention relates to the use of GC for the preparation of a pharmaceutical composition for the treatment of a patient in need of a GC-therapy, wherein said GC is to be administered to monocytes of said patient ex vivo. In a further embodiment, the present invention relates to a method for the preparation of a pharmaceutical composition comprising the step of contacting human monocytes ex vivo with a GC. A teflon container (e.g. a teflon bag) comprising a glucocorticoid and optionally a colony-stimulating factor (CSF) is also envisaged. In an even further embodiment, the present invention relates to a method of screening for a compound which is suitable for the treatment of a GC-responsive disease, said method comprising: a) contacting a monocyte with a compound to be tested; b) evaluating whether the monocyte is GC-induced; and thereby, c) identifying compounds which are suitable for the treatment of a GC-responsive disease. |
| priorityDate | 2010-03-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 635.